XNW29016

XNW29016 is an orally administered, selective **Poly(ADP-ribose) glycohydrolase (PARG) inhibitor** under development for the treatment of advanced solid tumors, particularly in patients who have failed standard therapies. It exhibits potent in vitro antitumor activity, including in cell lines resistant to PARP inhibitors, indicating potential utility in homologous recombination-deficient (HRD) and PARPi-resistant tumors. The drug is currently undergoing Phase I/II clinical trials to assess its safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy. Exploratory endpoints in trials include analyses of BRCA1/2 and other homologous recombination repair (HRR) pathway gene biomarkers to correlate with efficacy. The drug was initially developed by Evopoint Biosciences and is closely associated with Shan Dong Xin Nuo Wei Yi Yao Ke Ji You Xian Gong Si for ongoing studies[1][3][5][7][9].